Amplification of the MYCN oncogene occurs in 20-30% of all neuroblastoma cases and approximately 50% of high-risk tumors, strongly correlating with poor prognosis, relapse, and multidrug resistance. The gene discussed is MYCN; the disease is neuroblastoma.